[1] Mazzaferri EL, Jhiang SM.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5): 418-428.   doi: 10.1016/0002-9343(94)90321-2
[2] Mazzaferri EL.  Thyroid Remnant 131I Ablation for Papillary and Follicular Thyroid Carcinoma[J]. Thyroid, 1997, 7(2): 265-271.   doi: 10.1089/thy.1997.7.265
[3] Maxon HR, Thomas SR, Hertzberg VS, et al.  Relation Between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid Cancer[J]. N Engl J Med, 1983, 309(16): 937-941.   doi: 10.1056/NEJM198310203091601
[4] 刘斌, 田蓉, 欧晓红, 等.  分化型甲状腺癌转移灶碘代动力学及内照射吸收剂量的评估[J]. 中华核医学与分子影像杂志, 2016, 36(1): 63-66.   doi: 10.3760/cma.j.issn.2095-2848.2016.01.015
Liu B, Tian R, Ou XH, et al.  Evaluation of 131I biokinetics and its absorbed dose in patients with metastatic differentiated thyroid carcinoma[J]. Chin J Nucl Med Mol Imaging, 2016, 36(1): 63-66.   doi: 10.3760/cma.j.issn.2095-2848.2016.01.015
[5] Wierts R, Brans B, Havekes B, et al.  Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT[J]. J Nucl Med, 2016, 57(7): 1027-1032.   doi: 10.2967/jnumed.115.168799
[6]

Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging handbook: TNM classification of malignant tumors[M]. 6th ed. New York: Springer, 2002.
[7] 中华医学会核医学分会.  131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
Nuclear Medicine Association of the Chinese Medical Association.  131I guidelines of the treatment of differentiated thyroid carcinoma (version 2014)[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
[8] Fisher DR.  Internal dosimetry for systemic radiation therapy[J]. Semin Radiat Oncol, 2000, 10(2): 123-132.   doi: 10.1016/S1053-4296(00)80049-1
[9] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[10] Therasse P, Arbuck SG, Eisenhauer EA, et al.  New guidelines to evaluate the response to treatment in solid tumors[J]. J Natl Cancer Inst, 2000, 92(3): 205-216.   doi: 10.1093/jnci/92.3.205
[11] Flower MA, Schlesinger T, Hinton PJ, et al.  Radiation dose assessment in radioiodine therapy. 2. Practical implementation using quantitative scanning and PET, with initial results on thyroid carcinoma[J]. Radiother Oncol, 1989, 15(4): 345-357.   doi: 10.1016/0167-8140(89)90081-9
[12] 刘斌, 黄蕤, 曾宇, 等.  131I清除分化型甲状腺癌术后残留腺体的内照射吸收剂量与疗效的分析[J]. 中华核医学与分子影像杂志, 2014, 34(4): 279-282.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.003
Liu B, Huang R, Zeng Y, et al.  Relationship between internal radiation dose and outcome of radioiodine ablation of differentiated thyroid cancer[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4): 279-282.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.003
[13] Maxon HR, Englaro EE, Thomas SR, et al.  Radioiodine-131 Therapy for Well-Differentiated Thyroid Cancer—A Quantitative Radiation Dosimetric Approach: Outcome and Validation in 85 Patients[J]. J Nucl Med, 1992, 33(6): 1132-1136.